InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: None

Monday, 04/03/2017 3:14:08 PM

Monday, April 03, 2017 3:14:08 PM

Post# of 2099
Had no idea they completed 3 ph2 studies for vb-201.

http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-newsArticle&ID=2259170
======
VBL has studied VB-201 in five Phase 1 studies and three Phase 2 studies, some of which included patient populations known to have high rates of metabolic syndrome (e.g. psoriasis). In a retrospective analysis of liver enzyme tests performed for subjects dosed with VB-201, the Company identified a statistically significant time- and dose- dependent reduction of alkaline phosphatase (ALP) blood levels in patients treated orally with VB-201, which was reversed during a 4-week follow-up period after the patients completed the study.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News